To evaluate the efficacy of adding hydroxychloroquine to standard immunosuppressive therapy in high-risk patients with primary membranous nephropathy, with the aim of improving therapeutic outcomes and reducing disease-related complications.
Design
A Phase 3, randomized, parallel-group, double-blind, controlled clinical trial involving 50 patients. The Excel `rand` function was used for randomization.
Settings and conduct
Double-blind (study participants and assessors).
This randomized clinical trial is being conducted at Imam Reza and Ghaem hospitals in Mashhad. Patients are evaluated at baseline and six months after the start of treatment for proteinuria, serum albumin levels, blood pressure, and anti-PLA2R antibody levels and Scr
Participants/Inclusion and exclusion criteria
Study inclusion criteria:
- Age between 18 and 75 years
-Diagnosis of Primary Membranous Nephropathy via kidney biopsy.
- Persistent high-level proteinuria accompanied by hypoalbuminemia (exceeding 3.5 g/day) that persists after 6 months of maintenance therapy (ACEI or ARB).
-Proteinuria exceeding 8 g that persists after 3 months of maintenance therapy.
-Positive PLA2R antibody levels (>150) or a rising titer (increase of >25%) during maintenance therapy, reaching a level of 150.
- EGFR >30 mL/min.
Study exclusion criteria:
-History of hypersensitivity to hydroxychloroquine.
-Severe liver or heart disease.
- Pregnancy or breastfeeding.
-EGFR of less than 30 mL/min.
Intervention groups
Intervention group:
Standard immunosuppressive therapy (such as cyclophosphamide or rituximab) plus hydroxychloroquine at a dose of 200–400 mg/day for 6 months.
Control group:
Standard immunosuppressive therapy alone (without hydroxychloroquine).
Main outcome variables
The proteinuria of less than 300 mg in a 24-hour urine sample
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20261005071301N1
Registration date:2026-11-05, 1405/08/14
Registration timing:prospective
Last update:2026-11-05, 1405/08/14
Update count:0
Registration date
2026-11-05, 1405/08/14
Registrant information
Name
Farimah Amini
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 51 3891 4738
Email address
sadeghniar@mums.ac.ir
Recruitment status
Not yet recruiting
Funding source
Expected recruitment start date
2026-12-11, 1405/09/20
Expected recruitment end date
2027-06-10, 1406/03/20
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of Hydroxychloroquine Added to Standard Immunosuppression in High risk Membranous Nephropathy
Public title
Evaluation of The effect of Hydroxychloroquine on reducing proteinuria in High risk Membranous nephropathy patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Age greater than 18 and less than 75
Confirmed diagnosis of primary membranous nephropathy by a nephrologist via kidney biopsy
Persistent proteinuria level above 3.5 grams accompanied by hypoalbuminemia that continues after 6 months of treatment with an ACE inhibitors or ARB
Proteinuria above 8 grams that persists after 3 months of supportive treatment
Phospholipase A2 receptor antibody level above 150, or an increasing titer of more than 25% during supportive treatment that has reached a level of 150 or above
Relatively stable kidney function with GFR above 30
Exclusion criteria:
History of hypersensitivity to Hydroxychloroquine
Severe liver or heart disease
Pregnancy or breastfeeding
Chronic Kidney failure with GFR less than 30 ml/min
Irregular medication non-adherence
Age
From 18 years old to 75 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Care provider
Investigator
Outcome assessor
Sample size
Target sample size:
50
Randomization (investigator's opinion)
Randomized
Randomization description
Patients with a definite diagnosis by a nephrologist who have been included in the study and, based on randomization, are confirmed to be assigned to two groups: intervention and control, based on the combination of block 2 and 4 and 16 blocks of size 2 will be considered. The concealment method (in a closed opaque packet)will be used.
Blinding (investigator's opinion)
Double blinded
Blinding description
To maintain blinding, both groups are given two types of drugs. The intervention group is given hydroxychloroquine and standard treatment, and the control group is given standard drug and placebo. The placebo drug is completely similar in shape, color, and packaging to hydroxychloroquine. The allocation of groups is done by random code, and the patient and the treatment provider are unaware of the content of the codes. The person assigning the codes, the data analyst, the person responsible for drug preparation, and the safety and data monitoring committee are considered informed persons. Blinding (The subjects under study, the assessors, including the tor and the outcome assessor are blinded).
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Mashhad University of Medical Sciences
Street address
1st Floor, Faculty of Medicine, Mashhad University of Medical Sciences, Azadi Square, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9178833895
Approval date
2026-08-25, 1405/06/03
Ethics committee reference number
IR.MUMS.MEDICAL.REC.1405.236
Health conditions studied
1
Description of health condition studied
Primary Membranous Nephropathy
ICD-10 code
ICD-10 code description
Membranous nephro
Primary outcomes
1
Description
The treatment response is defined as proteinuria of less than 300 mg in a 24-hour urine sample, with measurements taken at two-month intervals
Timepoint
Measurement of proteinuria at baseline and then every two months up to 6 months
Method of measurement
24-hour urine collection
Secondary outcomes
empty
Intervention groups
1
Description
Intervention group: Standard immunosuppressive therapy comprising the Ponticelli regimen (methylprednisolone plus cyclophosphamide) or rituximab, combined with hydroxychloroquine (200–400 mg/day).
Category
Treatment - Drugs
2
Description
Control group: Standard immunosuppressive treatment only (without hydroxychloroquine)
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Imam Reza hospital
Full name of responsible person
Farimah Amini
Street address
Imam Reza Hospital, Imam Reza Square, Ibne sina Street, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3854 3031
Email
Emamreza@mums.ac.ir
2
Recruitment center
Name of recruitment center
Ghaem hospital
Full name of responsible person
Farimah Amini
Street address
Ghaem Hospital, Ahmadabad Street, Dr. Shariati Square, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3801 2000
Email
Quaem.Medical.Center@mums.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Tafaghodi, Mohsen
Street address
The eastern gate of the university campus, Azadi Square, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9177948560
Phone
+98 51 3800 2000
Email
MDS.Dean@mums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mashhad University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Farimah Amini
Position
Nephrology subspecialty fellow
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Unit 20, Hadish Building, No. 48, between Rahimzadeh 3 and 5, Saremi 54, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9178833895
Phone
+98 51 3891 4738
Fax
Email
farimah.amini8784@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Farimah Amini
Position
Nephrology subspecialty fellow
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Unit 20, Hadish building, No. 48, between Rahimzadeh 3 and 5, Saremi 54, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9178833895
Phone
+98 51 3891 4738
Fax
Email
farimah.amini8784@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Farimah Amini
Position
Subspecialty Nephrology Assistant
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Unit 20, Hadish building, No. 48, between Rahimzadeh 3 and 5, Saremi 54, Mashhad
City
Mashhad
Province
Razavi Khorasan
Postal code
9178833895
Phone
+98 51 3891 4738
Fax
Email
farimah.amini8784@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available